Is APPY a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

490 people get APPY articles and Market Currents by email alert.

Get email alerts on APPY »

HEADLINES:

Venaxis Announces Pricing of Offering of Common Stock and Warrants

PR Newswire (Thu, 7:03PM)
Venaxis Poised For Run-Up Into Pivotal Study Results
Mike Havrilla • Sun, Apr 28 • 7 Comments
Venaxis Appoints SomaLogic CMO and former Pfizer Executive Stephen A. Williams, M.D., Ph.D., to Board of Directors

PR Newswire (Apr 18, 2013)
Venaxis Management Discusses Q4 2012 Results - Earnings Call Transcript
Tue, Mar 26
Pivotal Phase III Trial Data Ahead For 3 Development-Stage Small Pharma Companies
Chemistfrog • Tue, Mar 26 • 4 Comments
Venaxis: Appendicitis Screening Just Became Cheaper
Doolan Wesley • Wed, Feb 27 • 2 Comments
Venaxis' 'APPY1' Set For Great Year
James Stephens • Thu, Feb 7 • 9 Comments
4 Small Biotechs With Big Clinical Trials Presenting In 2013
Brian L. Wilson • Wed, Jan 30 • 14 Comments
Venaxis Still Faces Challenges For Its APPY1 Test
Brian L. Wilson • Wed, Jan 9 • 16 Comments
AspenBio Pharma Announces Closing of Public Offering of 1,946,000 Shares of Common Stock

PR Newswire (Nov 20, 2012)
AspenBio Pharma Announces Pricing of Public Offering of 1,476,000 Shares of Common Stock

PR Newswire (Nov 14, 2012)
AspenBio Pharma Announces Proposed Public Offering

PR Newswire (Nov 14, 2012)
AspenBio Pharma Management Discusses Q3 2012 Results - Earnings Call Transcript
Tue, Nov 13, 2012
AspenBio to Present at 2012 Lazard Capital Markets Healthcare Conference

PR Newswire (Nov 13, 2012)
AspenBio Pharma Begins Training Hospital Sites for Pivotal Clinical Trial

PR Newswire (Nov 13, 2012)
AspenBio Engages European-based Sales and Marketing Veteran Miquel Vernet to Consult on European Commercialization

PR Newswire (Nov 6, 2012)
AspenBio Pharma to Provide Third Quarter 2012 Business Update

PR Newswire (Nov 5, 2012)
A Balanced, Scientific View Of AspenBio Biopharma (Soon To Be Venaxis)
amirstep • Wed, Oct 24, 2012 • 1 Comment
AspenBio Proposes Corporate Name Change to Venaxis, Inc.

PR Newswire (Oct 15, 2012)
5 Healthcare Companies With Insider Buying During September 2012 - Part II
Markus Aarnio • Wed, Oct 3, 2012 • 13 Comments

To learn more about Seeking Alpha Pro, click here.

Venaxis Poised For Run-Up Into Pivotal Study Results
Mike Havrilla • Sun, Apr 28 • 7 Comments
Venaxis: Appendicitis Screening Just Became Cheaper
Doolan Wesley • Wed, Feb 27 • 2 Comments
Venaxis' 'APPY1' Set For Great Year
James Stephens • Thu, Feb 7 • 9 Comments
Venaxis Still Faces Challenges For Its APPY1 Test
Brian L. Wilson • Wed, Jan 9 • 16 Comments
A Balanced, Scientific View Of AspenBio Biopharma (Soon To Be Venaxis)
amirstep • Wed, Oct 24, 2012 • 1 Comment
6 Reasons To Buy AspenBio Pharma
Markus Aarnio • Thu, Jul 26, 2012 • 13 Comments
Aspen BioPharma: Anticipating Active '09
Mike Havrilla • Wed, Dec 31, 2008
AspenBio Pharma: Poised to Ascend New Heights
Mike Havrilla • Sun, Jan 6, 2008 • 1 Comment

Pivotal Phase III Trial Data Ahead For 3 Development-Stage Small Pharma Companies
Chemistfrog • Tue, Mar 26 • 4 Comments
4 Small Biotechs With Big Clinical Trials Presenting In 2013
Brian L. Wilson • Wed, Jan 30 • 14 Comments
5 Healthcare Companies With Insider Buying During September 2012 - Part II
Markus Aarnio • Wed, Oct 3, 2012 • 13 Comments
5 Healthcare Stocks With Insider Buying Filed On August 6-10
Markus Aarnio • Mon, Aug 13, 2012 • 2 Comments
3 Healthcare Companies Seeing Insider Buying In Last 3 Days - Part II
Markus Aarnio • Mon, Jul 2, 2012
Small Biotech Companies: Please Tread Carefully
Doolan Wesley • Tue, Jun 26, 2012
Best and Worst Performing U.S. Stocks YTD
Bespoke Investment Group • Mon, Jul 26, 2010
4 Small Cap Biotechs to Keep an Eye On
Inflection Point Investing LLC • Wed, May 26, 2010 • 9 Comments
Thursday Outlook: What, Me Worry?
Philip Davis • Thu, May 13, 2010 • 64 Comments
Wild Weekly Wrap Up: Cash Is King
Philip Davis • Mon, May 3, 2010 • 18 Comments
Biotech CROs Take Center Stage in Recent Deals
The Burrill Report • Sun, May 2, 2010 • 1 Comment
Preview of AspenBio's Potentially Blockbuster Clinical Trials
Dan Weiss • Sun, Apr 25, 2010 • 15 Comments
Friday Options Recap
Frederic Ruffy • Fri, Apr 23, 2010 • 2 Comments
AspenBio Pharma Poised for a Breakout Year
Dan Weiss • Tue, Jan 19, 2010 • 3 Comments
Extreme FDA Trades: 20 Stocks Under 5 Bucks
Mike Havrilla • Tue, Jul 21, 2009 • 3 Comments
AspenBio: Bursting with Possibilities
Dan Weiss • Sun, Jul 19, 2009 • 7 Comments
Medical Device Trades: 7 Stocks Under 5 Bucks
Mike Havrilla • Mon, Jul 6, 2009
FDA Calendar Updates: AspenBio, CytRx, Cephalon, Pozen, Sanofi, AMAG
Mike Havrilla • Wed, Jul 1, 2009 • 2 Comments
FDA Calendar Updates: Acusphere, AspenBio, Alkermes
Mike Havrilla • Tue, May 19, 2009 • 3 Comments
FDA Calendar Updates: AspenBio, Acrux, Isolagen, Human Genome Sciences
Mike Havrilla • Mon, Mar 16, 2009

Venaxis Management Discusses Q4 2012 Results - Earnings Call Transcript
Tue, Mar 26
AspenBio Pharma Management Discusses Q3 2012 Results - Earnings Call Transcript
Tue, Nov 13, 2012

Venaxis Announces Pricing of Offering of Common Stock and Warrants

PR Newswire (Thu, 7:03PM)
Venaxis Appoints SomaLogic CMO and former Pfizer Executive Stephen A. Williams, M.D., Ph.D., to Board of Directors

PR Newswire (Apr 18, 2013)
AspenBio Pharma Announces Closing of Public Offering of 1,946,000 Shares of Common Stock

PR Newswire (Nov 20, 2012)
AspenBio Pharma Announces Pricing of Public Offering of 1,476,000 Shares of Common Stock

PR Newswire (Nov 14, 2012)
AspenBio Pharma Announces Proposed Public Offering

PR Newswire (Nov 14, 2012)
AspenBio to Present at 2012 Lazard Capital Markets Healthcare Conference

PR Newswire (Nov 13, 2012)
AspenBio Pharma Begins Training Hospital Sites for Pivotal Clinical Trial

PR Newswire (Nov 13, 2012)
AspenBio Engages European-based Sales and Marketing Veteran Miquel Vernet to Consult on European Commercialization

PR Newswire (Nov 6, 2012)
AspenBio Pharma to Provide Third Quarter 2012 Business Update

PR Newswire (Nov 5, 2012)
AspenBio Proposes Corporate Name Change to Venaxis, Inc.

PR Newswire (Oct 15, 2012)
AspenBio Plans to Initiate Pivotal Study in Fourth Quarter

PR Newswire (Sep 27, 2012)
AspenBio to Provide Investors with Clinical and Business Update

PR Newswire (Sep 25, 2012)
AspenBio to Present at 2012 Aegis Healthcare Conference

PR Newswire (Sep 20, 2012)
AspenBio Announces Dismissal of Class Action and Chipman Lawsuits by U. S. District Court

PR Newswire (Sep 18, 2012)
AspenBio to Present at Rodman & Renshaw Annual Global Investment Conference

PR Newswire (Sep 4, 2012)
AspenBio Pharma Focuses Resources on Development of AppyScore™ Clinical Diagnostic Test

PR Newswire (Aug 15, 2012)
AspenBio Pharma to Provide Shareholders with Business Update

PR Newswire (Aug 8, 2012)
AspenBio Pharma Submits Pre-IDE Information Package to FDA for AppyScore™ Appendicitis Test System

PR Newswire (Aug 7, 2012)
AspenBio Pharma Enhances Product Development & Manufacturing Capabilities in Preparation for Clinical Trial and Commercialization of AppyScore™

PR Newswire (Aug 1, 2012)
AspenBio Pharma Executes Worldwide License Agreement for its Animal Health Assets

PR Newswire (Jul 30, 2012)

APPY vs. ETF Alternatives

Company Description

Currently, there's no company description for APPY.

Sector: Healthcare

Industry: Diagnostic Substances

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Friday, May 24, 11:52 AM Venaxis (APPY -5%) slips today after pricing its 10M shares and related warrants to purchase 3.5M shares at a combined public price of $1.25 per share with an exercise price of $1.36. The offering is expected to close on May 30. Venaxis should realize approximately $11.1M in net proceeds from the sale, for which it intends to use primarily for funding of further clinical development and seeking FDA clearance for APPY1, as well as for initial commercialization of the drug in the U.S. and the E.U. Comment! [Healthcare, On the Move]
Friday, May 24, 9:10 AM Premarket gainers: BLOX +17%. IOC +15%. YGE +13%. P +11%. MRVL +5%.
Losers: DF -52%. SHLD -16%. AVEO -15%. RSOL -13%. TITN -11%. APPY -7%. ANF -7%. CRM -5%. 2 Comments [On the Move]
Tuesday, March 26, 8:09 PM Venaxis Inc. (APPY) climbs in the post-trade session after providing an update on its clinical and commercial activities, reporting in its 10-K that it continues to enroll patients into its ongoing clinical study of APPY1, and it anticipates completing the study and potentially filing with the FDA for regulatory clearance by year end. Read more on its Business Update Conference Call Here: Business Update Transcript. Shares +5% AH. Comment! [Healthcare, Earnings, On the Move]
Monday, February 25, 12:53 PM Midday top 10 gainers: ENMD +26%. OBCI +25%. GALT +19%. APPY +15%. NTWK +12%. BKS +12%. ZNGA +11%. HXM +10%. MGN +10%. CMGE +9%.
Midday top 10 losers: AFFY -86%. CEDC -55%. DVAX -33%. GGS -31%. GMXR -24%. TROV -17%. EMITF -16%. ESI -14%. FRO -14%. XRSC -13%. Comment! [On the Move]
Monday, February 25, 10:43 AM Shares of beaten-down Venaxis (APPY +18.2%) are soaring today after Canaccord upgraded the stock to Buy and nearly tripled its price target to $7.00 from $2.50. The firm says that APPY's pursuit of a blood test to identify those at low risk for appendicitis is compelling, considering that appendicitis is the most-common non-traumatic childhood surgical disease. FDA approval could come before mid-2014 and the U.S. market alone could be nearly $700M. Comment! [Healthcare, On the Move]
Thursday, February 7, 9:14 AM Premarket gainers: OXGN +31%. SUTR +29%. DV +18%. BIOL +9%. AAP +9%. ORLY +9%. APPY +7%. LF +6%.
Losers: AKAM -18%. TQNT -11%. ARAY -9%. ANN -9%. GMCR -9%. NXST -6%. BBEP -6%. MWW -6%. BG -5%. ATML -5%. Comment! [On the Move]
Tuesday, January 8, 1:45 PM Venaxis (APPY -9.6%) slips today, despite its announcement late yesterday that European regulators have approved the company's blood-based appendicitis test APPY1. Initial sales are slated to begin during Q1 in key territories, including the UK, Italy, France, Germany and Benelux countries. The company expects to announce agreements with top EU distributors beginning in the first quarter 2013. Comment! [Healthcare, On the Move]
Tuesday, January 8, 9:10 AM Premarket gainers: PERI +19%. STSI +16%. CTIC +8%. PPHM +5%.
Losers: GME -10%. APPY -6%. CY -6%. CLMT -5%. Comment! [On the Move]
Friday, December 21, 2012, 9:10 AM Premarket gainers: HALO +19%. CEMI +17%. ASCA +17%. APPY +14%. RHT +5%. PNK +5%. SHP +5%.
Losers: ECTE -18%. RIMM -14%. ALU -7%. 1 Comment [On the Move]
Thursday, November 15, 2012, 10:30 AM AspenBio Pharma (APPY -13.8%) falls after pricing its previously announced secondary offering of 1.5M shares at $2.10 each, a 15% discount to Wednesday's close. The diagnostic-product developer has a 7.7M share float outstanding at the beginning of November. Comment! [Healthcare, On the Move]
Thursday, November 15, 2012, 9:10 AM Premarket gainers: BXG +68%. ACRX +31%. DANG +14%. NTAP +12%. ELOQ +12%. AMRN +7%. LPH +7%.
Losers: VELT -27%. DMND -23%. APPY -17%. TDG -6%. AKS -5%. DRYS -5%. VGR -5%. NGLS -5%. Comment! [On the Move]
Wednesday, November 14, 2012, 5:08 PM AspenBio Pharma (APPY) announces a secondary offering for an undisclosed amount of its common stock. The company intends to use the net proceeds for general corporate purposes, which includes conducting a clinical trial for its blood-based appendicitis test, and for working capital purposes. Aegis Capital is acting as the sole book-running manager for the offering. Shares -8.5% AH. Comment! [Healthcare]
Tuesday, October 16, 2012, 12:45 PM Midday top 10 gainers: NOOF +54%. DSTI +37%. INVE +31%. BCOM +17%. PAMT +16%. PRXI +16%. TRT +16.%. APPY +13%. ARL +12%. RLGT +11%. Top 10 Losers: AONE -75%. RATE -24%. OSG -22%. KFS -19%. ISIS -18%. VRML -18%. CLWR -15%. OCZ -11%. CMRE -11%. VIMC -10%. 1 Comment [On the Move]
Tuesday, October 9, 2012, 12:45 PM Midday top 10 gainers: BSDM +73%. ALDA.PK +28%. APPY +22%. RITT +19%. OTT +17%. TRT +17%. HOLL +15%. PRPH +13%. PBM +13%. BIOF +12%.
Top 10 Losers: VDSI -23%. MGT -22%. EW -19%. THM -19%. GLUU -18%. PVA -16%. PAMT -15%. ANGO -13%. VRNG -11%. UNIS -10%. 1 Comment [On the Move]
Thursday, September 27, 2012, 12:45 PM Midday top 10 gainers: CTC +71.53%. ROYL +31.38%. APPY +18.48%. TPX +16.5%. ULTR +15.6%. WZE +13.09%. STRM +12.7%. IGLD +12.62%. PNX +11.22%. PRAN +11.17%.
Top 10 Losers: PPHM -35.54%. CAFI -12.94%. SYUT -10.64%. CPHD -9.58%. MTE -9.02%. MITK -8.92%. CHYR -8%. CYTX -7.76%. FUL -7.37%. UBNT -7.07%. Comment! [On the Move]
Thursday, September 27, 2012, 10:06 AM AspenBio (APPY +4.3%) intends to start a pivotal trial of its AppyScore blood-based appendicitis test in Q4 after receiving feedback from the FDA. With the diagnostic-product developer's increased focus on AppyScore, four out of nine board members have stepped down. While AspenBio plans to appoint new directors, it also intends to ultimately maintain a smaller board. (PR) Comment! [Healthcare, On the Move]

shawn d
$APPY now at bottom. News coming out great buy! Buy now thank me later.
Thu, 2:03 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

anomaly1
Load up $APPY 1.69 ... big investor going to buy shares as an initial investment IMO
Mon, 11:09 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

shawn d
$APPY is a strong buy. If they arent at the bottom, they are close Buy and enjoy the ride,could be quick and very profitable. Thank Me Later
May 17, 9:34 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Chemistfrog
$APPY sold off a bit last week and recovered Friday. I sold 1/2 into strength and am holding remainder..
Apr 20, 7:31 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

smokeyRose
Shouldn't A co. E-mail shareholders when they are going to Float more stock! like what $APPY Did! jeepers Creepers
11/23/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

smokeyRose
lots of Vol on CLNE My Biggest Drop is 10.91% on APPY
11/15/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

smokeyRose
YDNX YUM NGVC APPY What the heck is going on with these guys!!!
10/5/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

smokeyRose
APPY and FDO Lets hope the best for APPY
10/3/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Num1PeckerHead
I believe that APPY is about to turn the corner with their recent raise and are in the starting gate ready to start their pivotal trial ...
7/5/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

freefdawatchlist
http://bit.ly/K1K9qi Top gainer $USU $FBN $BBX $NBG $SLCA $APPY $WEST.OB $MFI $DNDN $KITD.OB
6/13/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

APPY Venaxis, Inc.

APPY

Venaxis, Inc.